Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Pablo Velasco Puyó, Alfredo Tagarro, Susana Garcia-Obregon, Olatz Villate Bejarano, Cinta Moraleda, Jorge Huerta Aragonés, Eduardo J Bardón Cancho, Anna Faura Morros, Víctor Galán-Gómez, Laura Escobar Fernández, Francisco Lendinez-Molinos, Blanca Herrero Velasco, Laura Ureña Horno, Nerea Domínguez-Pinilla, Juan Francisco Pascual Gazquez, Cristina Nova Lozano, Marta Osuna-Marco, Inés Marín-Cruz, Irene Gomez Pastrana, Nagore Garcia de Andoin Barandiaran, Nerea Gallego Mingo, Raquel Portugal Rodríguez, Adela Cañete, Marta Pareja León, Sara Castrillo Bustamante, María Tallón García, Almudena Gónzalez-Prieto, María Solé-Rodríguez, Macarena González Cruz, Antonio Soriano-Arandes, Miriam Mota, Santiago Pérez-Hoyos, Lucas Moreno, Itziar Astigarraga
The EPICO (Spanish general registry of COVID-19 in children)-SEHOP (Spanish Society of Pediatric Hematology and Oncology) platform gathers data from children with SARS-CoV-2 in Spain, allowing comparison between children with cancer or allogeneic hematopoietic stem cell transplantation (alloHSCT) and those without. The infection is milder in the cancer/alloHSCT group than in children without comorbidities (7.1% vs. 14.7%), except in children with recent alloHSCT (less than 300 days), of which 35.7% experienced severe COVID-19...
June 2, 2024: Pediatric Blood & Cancer
#2
JOURNAL ARTICLE
Federica Galaverna, Sara Flamini, Carmen Dolores De Luca, Ilaria Pili, Emilia Boccieri, Francesca Benini, Francesco Quagliarella, Chiara Rosignoli, Marco Rosichini, Shirley Genah, Marialuigia Catanoso, Antonella Cardinale, Gabriele Volpe, Marianna Coccetti, Angela Pitisci, Giuseppina Li Pira, Roberto Carta, Barbarella Lucarelli, Francesca Del Bufalo, Valentina Bertaina, Marco Becilli, Daria Pagliara, Mattia Algeri, Pietro Merli, Franco Locatelli, Enrico Velardi
Mucosal-associated invariant T (MAIT) cells are innate-like T-cells implicated in the response to fungal and bacterial infections. Their contribution to restoring T-cell immunity and influencing hematopoietic stem cell transplant (HSCT) outcomes remains poorly understood. We retrospectively studied MAIT-cell recovery in 145 consecutive children and young adults with hematological malignancies undergoing allo-HSCT, between April/2019 and May/2022, from unrelated matched donor (MUD, n=52), with standard graft-versus-host-disease (GvHD) prophylaxis, or HLA-haploidentical (Haplo, n=93) donor after in vitro αβT/CD19-cell depletion, without post-HSCT pharmacological prophylaxis...
May 30, 2024: Haematologica
#3
JOURNAL ARTICLE
Rawan Al Khudari, Dalal Doba, Amjad Esmandar, Maged Kheder
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a therapeutic approach known for its high success rates in treating various hematologic malignancies, hemoglobinopathies, immune deficiencies, and other disorders. Notably, pediatric HSCT commenced in Syria in 2021 amidst the prevailing crisis. This study aims to assess the demographic and clinical profiles of pediatric patients who underwent stem cell transplantation and to analyze treatment outcomes at Syria's inaugural pediatric HSCT center...
August 2024: Pediatric Transplantation
#4
JOURNAL ARTICLE
Qingwei Wang, Yixin Hu, Li Gao, Senlin Zhang, Jun Lu, Bohan Li, Jie Li, Yanhua Yao, Shengqin Cheng, Peifang Xiao, Shaoyan Hu
Acute myeloid leukemia (AML) with t(8;21) (q22;q22), which forms RUNX1::RUNX1T1 fusion gene, is classified as a favorable-risk group. However, the presence of mutations in KIT exon 17 results in an adverse prognosis in this group. Avapritinib, a novel tyrosine kinase inhibitor, was designed to target KIT mutation. We report a retrospective study of four pediatric patients with AML with t(8:21) and KIT exon 17 mutation who were treated with avapritinib, three of them failed to demethylate drugs and donor lymphocyte infusion targeting RUNX1::RUNX1T1-positivity after allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
May 28, 2024: Annals of Hematology
#5
JOURNAL ARTICLE
Sıdıka Gülkan Özkan, Ali Kimiaei, Ali Hakan Kaya, Mehmet Sezgin Pepeler, Hasan Atilla Özkan, Mutlu Arat
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a widely utilized treatment for various hematological diseases. While selection criteria for unrelated donors are well-established, there is a lack of consistency and standardization in the selection of related donors. To investigate the current approach of hematologists to the selection of relative donors at Turkish hematopoietic stem cell transplantation (HSCT) centers. The study employed a cross-sectional survey design, distributing a self-administered questionnaire to 95 adult and pediatric transplantation centers in Turkey to investigate their approach to related donor selection for allo-HSCT...
May 27, 2024: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
#6
JOURNAL ARTICLE
Li Li, Xiaoli Zhen, Wenjian Wang
BACKGROUND: Mucormycosis is a fatal invasive fungal infection that commonly affects immunocompromised children. The aim of our study was to investigate the clinical manifestations, treatments, and prognosis of pediatric patients with mucormycosis. METHODS: We conducted a retrospective search in Shenzhen Children's Hospital from July 2013 to July 2023 for all patients with mucormycosis. The clinical manifestation, pathogen detection, radiology, treatments, and prognosis were analyzed...
2024: Infection and Drug Resistance
#7
JOURNAL ARTICLE
Takuto Takahashi, Alexander J Lake, Franziska Wachter, Francesca Alvarez Calderon, Christopher Dandoy, Amy K Keating
BACKGROUND: The implications of previous central nervous system (CNS) involvement in children with acute myeloid leukemia (AML) undergoing hematopoietic cell transplantation (HCT) remain inadequately understood. Patients with CNS disease require more upfront CNS directed intrathecal therapy, but little is known about whether transplant conditioning regimens should be intensified or if previous CNS involvement impacts post HCT outcomes. While total body irradiation (TBI) remains standard for pediatric acute lymphoblastic leukemia myeloablative conditioning, it has been largely replaced with chemotherapy-only myeloablation in pediatric AML, primarily due to toxicity and late effects associated with TBI...
May 18, 2024: Transplantation and cellular therapy
#8
REVIEW
Julie Lillian Pimentel Justus, Miriam P Beltrame, Ana Paula de Azambuja, Yara C Schluga, Edna A Martins, Maria Tadeu Lemes Rocha, Adriana Mello Rodrigues, Gisele Loth, Alberto Cardoso Martins Lima, Carmem Bonfim
BACKGROUND AIMS: Adequate re-establishment of thymopoiesis is critical for long-term immune reconstitution after hematopoietic cell transplantation (HCT), potentially impacting patient survival rates. This study aimed to evaluate immune reconstitution in pediatric HCT recipients by quantifying recent thymic emigrants (RTEs), specifically CD3+ CD31+ CD45RA+ cells. METHODS: We conducted a retrospective analysis of 186 pediatric patients transplanted between 2013 and 2020, undergoing their first allogeneic HCT, who were alive in the first 100 days after transplantation with immune recovery evaluation at three time points: day 100, day 180 and day 360 after HCT...
May 1, 2024: Cytotherapy
#9
JOURNAL ARTICLE
Nicolas Poirier, Valérie Paquin, Séverine Leclerc, Véronique Lisi, Carolina Marmolejo, Hicham Affia, Paulo Cordeiro, Yves Théorêt, Elie Haddad, Gregor Andelfinger, Vincent Philippe Lavallée, Michel Duval, Sabine Herblot
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the standard of care for chemotherapy-refractory leukemia patients, but cure rates are still dismal. To prevent leukemia relapse following HSCT, we aim to improve the early graft-versus-leukemia effect mediated by natural killer (NK) cells. Our approach is based on the adoptive transfer of Therapeutic Inducers of Natural Killer cell Killing (ThINKK). ThINKK are expanded and differentiated from HSC, and exhibit blood plasmacytoid dendritic cell (pDC) features...
May 15, 2024: Journal for Immunotherapy of Cancer
#10
JOURNAL ARTICLE
Senlin Zhang, Minyuan Liu, Qingwei Wang, Shuran Wang, Xin Liu, Bohan Li, Jie Li, Junjie Fan, Shaoyan Hu
BACKGROUND: The risk factors for hemorrhagic cystitis (HC) in children undergoing hematopoietic stem cell transplantation (HSCT) are unclear. Therefore, we conducted this systematic review and meta-analysis to investigate the risk factors for HC in children undergoing HSCT. METHODS: We performed this meta-analysis by retrieving studies from PubMed, EMBASE, and the Cochrane Library up to October 10, 2023, and analyzing those that met the inclusion criteria. I2 statistics were used to evaluate heterogeneity...
May 14, 2024: BMC Pediatrics
#11
REVIEW
Madelyn Burkart, Shira Dinner
There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-type chemotherapy protocols in younger adults as well as chemotherapy light approaches in older adults and the incorporation of measurable residual disease (MRD) testing to inform clinical decision making. With this, treatment outcomes in adult Ph- ALL have improved across all age groups...
April 25, 2024: Blood Reviews
#12
JOURNAL ARTICLE
Shannon Herzog, Ryan Shanley, Shernan G Holtan, Margaret L MacMillan, Daniel J Weisdorf, Najla El Jurdi
BACKGROUND: Post-transplant cyclophosphamide (PTCy) following hematopoietic cell transplantation (HCT) has emerged as standard of care for graft-versus-host disease (GVHD) prevention in adult patients without increasing malignant relapse. We previously defined acute GVHD (aGVHD) treatment response categories as either corticosteroid-sensitive (SS), dependent (SD), or resistant (SR) based on response to first-line corticosteroids and reported their clinical outcomes following non-PTCy based prophylaxis...
May 9, 2024: Transplantation and cellular therapy
#13
JOURNAL ARTICLE
Cassandra P Wang, Juanita E Ferreira, Alexander Placek, Paibel Aguayo-Hiraldo, Gordana Raca, Brent L Wood, Karin P Miller, Thomas Coates, David R Freyer, Alexandra E Kovach
Germline variants of the RUNX1 gene are associated with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies (RUNX1-FPDMM), which is characterized by an increased risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia. Patients with FPDMM have also been described to develop B- or T-cell acute lymphoblastic leukemia. We present a pediatric patient with RUNX1-FPDMM that evolved into concurrent MDS and T-cell acute lymphoblastic leukemia after a decade of monitoring with serial blood counts...
May 11, 2024: Leukemia & Lymphoma
#14
COMPARATIVE STUDY
Utku Aygunes, Barbaros Sahin Karagun, Ilgen Sasmaz, Bülent Antmen
BACKGROUND: Oral mucositis is one of the side effects developed post-hematopoietic stem cell transplant. This retrospective study aimed to assess the efficacy of a mouthwash mixture (lidocaine, sodium alginate, sucralfate, pheniramine) versus hyaluronic acid and a solution of sodium bicarbonate in terms of healing time and weight gain in the treatment of oral mucositis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation with hemato-oncological malignancies...
May 2024: Klinische Pädiatrie
#15
JOURNAL ARTICLE
Adam Alexandersson, Mikko S Venäläinen, Nelli Heikkilä, Xiaobo Huang, Mervi Taskinen, Pasi Huttunen, Laura L Elo, Minna Koskenvuo, Eliisa Kekäläinen
We studied the associations between inflammation-related proteins in circulation and complications after pediatric allogenic hematopoietic stem cell transplantation (HSCT), to reveal proteomic signatures or individual soluble proteins associated with specific complications after HSCT. We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution and blood viral copy numbers in 27 children (1-18 years of age) during a 2-year follow-up after allogenic HSCT...
May 10, 2024: Immunology and Cell Biology
#16
JOURNAL ARTICLE
Marina Ascunce, Alejandra Coccolo, Yasmina Mozo, Fernando Baquero-Artigao, Paula Rodriguez-Molino, Carlos Toro-Rueda, Paloma García-Clemente, Elena Sánchez-Zapardiel, Eduardo López-Granados, Dolores Corral-Sánchez, David Bueno, Luisa Sisinni, Antonio Pérez-Martínez, Cristina Calvo, Teresa Del Rosal
Hematopoietic stem cell transplant recipients are prone to infectious complications. Infections caused by nontuberculous mycobacteria have increased in adults but literature in children is scarce. We report 6 episodes of disseminated or pulmonary nontuberculous mycobacteria infection among 5 pediatric hematopoietic stem cell transplant recipients. All but one were caused by Mycobacterium avium complex. Four patients died, 2 related to nontuberculous mycobacteria infection.
May 7, 2024: Pediatric Infectious Disease Journal
#17
JOURNAL ARTICLE
Ke Tong, Yan Meng, Luying Zhang, Xiaoying Lei, Qihui Liu, Xianmin Guan, Jie Yu, Ying Dou
Cardiotoxicity in children is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT); therefore, early identification of risk factors can improve patient prognosis. However, there are few data on the clinical characteristics of early-stage cardiotoxicity in children after allo-HSCT. We conducted a retrospective single-center study of pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2016 and December 2022 at the Children's Hospital Affiliated with Chongqing Medical University to evaluate the clinical characteristics of early cardiac events (ECEs) after allo-HSCT and their impact on survival outcomes...
May 6, 2024: Annals of Hematology
#18
JOURNAL ARTICLE
Matteo Tanzi, Enrica Montini, Agnese Rumolo, Antonia Moretta, Patrizia Comoli, Gloria Acquafredda, Jessica Rotella, Gloria Taurino, Francesca Compagno, Francesco Delle Cave, Cesare Perotti, Gian Luigi Marseglia, Marco Zecca, Daniela Montagna
BACKGROUND AIMS: Somatic cell therapy based on the infusion of donor-derived cytotoxic T lymphocytes (CTL) able to recognize patients' leukemia blasts (LB) is a promising approach to control leukemia relapse after allogeneic HSCT. The success of this approach strongly depends on the ex vivo generation of high-quality donor-derived anti-leukemia CTL in compliance with Good Manufacturing Practices (GMP). We previously described a procedure for generating large numbers of donor-derived anti-leukemia CTL through stimulation of CD8-enriched lymphocytes with dendritic cells (DCs) pulsed with apoptotic LB in the presence of interleukin (IL)-12, IL-7 and IL-15...
April 20, 2024: Cytotherapy
#19
JOURNAL ARTICLE
Ting Zhao, Hui-Lan Zhang, Hao Shen, Jie Feng, Ting-Ting Wang, Hong-Jian Li, Lu-Hai Yu
PURPOSE: We aimed to investigated the influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: This was a prospective cohort design study. High-performance liquid chromatography-mass spectrometry was employed to monitor voriconazole concentration. First-generation sequencing was performed to detect gene polymorphisms. Indicators of liver function were detected at least once before and after voriconazole therapy...
May 3, 2024: BMC Pediatrics
#20
JOURNAL ARTICLE
Wei Zhao, Rong Wang, Man Chen
BACKGROUND: Air-leak syndrome (ALS) is considered as an independent risk factor for poor prognosis in adult patients who had received hematopoietic stem cell transplantation (HSCT), and the 5-year overall survival (OS) of ALS is less than 30%. However, the clinical features of ALS among post-transplant pediatric patients have rarely been explored. PROCEDURES: We retrospectively reviewed 2206 pediatric patients who had received an allo-HSCT between January 2013 and December 2019 at the Hebei Yanda Lu Daopei Hospital, and analyzed the role of ALS in prognosis following HSCT...
April 26, 2024: Pediatric Blood & Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
